Technology | April 22, 2011

FDA Clears Trifecta Stented Tissue Aortic Valve

April 22, 2011 – The U.S. Food and Drug Administration (FDA) has cleared the Trifecta valve, by St. Jude Medical. The valve, a clinically-proven replacement for diseased, damaged or malfunctioning aortic heart valves, mimics the flow of a natural, healthy heart. The valve was designed for excellent hemodynamic performance (the optimization of blood flow through the valve) and long-term durability. To ensure the structural integrity of the valve, it is constructed using a polyester and tissue-covered titanium stent, or base. The valve features leaflets manufactured from pericardial tissue attached to the exterior of the valve stent. This design allows the leaflets to open more fully and efficiently, mimicking the performance of a healthy aortic heart valve and limiting tissue abrasion through tissue-to-tissue (stent-to-leaflet) contact. Also contributing to the valve’s durability, it offers the Linx AC Technology, an anticalcification treatment designed to reduce tissue mineralization (hardening), one of the primary causes of valve deterioration. It also offers several features that improve the ease of implantation, including the valve’s unique holder, designed to improve visibility and cuff access for suturing, and customized sizes. “Physicians around the world have already voiced tremendous excitement and satisfaction with the Trifecta valve,” said Frank J. Callaghan, president of the St. Jude Medical cardiovascular division. “Trifecta has demonstrated outstanding hemodynamic performance and has improved the lives of patients with aortic valve disease.” The valve was approved by regulatory authorities in Europe and Canada in 2010. For more information: www.sjm.com


Related Content

Products | Guidewires| July 28, 2015
The Safari2 Pre-Shaped Guidewire.
Feature | Heart Valve Repair| July 28, 2015
Boston Scientific announced CE Mark and U.S. Food and Drug Administration (FDA) clearance for the Safari2 Pre-Shaped...
Direct Flow Medical, Transcatheter Aortic Valve System, SALUS Trial, FDA
News | Heart Valve Repair| July 22, 2015
Direct Flow Medical Inc. received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug...
GlobalData, TAVR, Edwards, Medtronic, CoreValve Evolut R, Sapien 3

Sapien 3 image courtesy of Edwards Lifesciences

News | Heart Valve Repair| July 21, 2015
The recent U.S. Food and Drug Administration (FDA) approvals of two next-generation transcatheter aortic valve...
ACC, health policy statement, heart team, cardiovascular health
Feature | Cardiovascular Surgery| July 17, 2015
Building teams that include advanced practice providers can help cardiovascular practices meet the challenges of modern...
Biotronik, TAVI device, BIOVALVE trial, Hamburg, Germany
News | Heart Valve Repair| July 14, 2015
Biotronik announced the completion of the BIOVALVE first-in-human trial for its new transcatheter aortic valve. Study...
CardiAQ, Edwards, acquire, acquisition, Fortis, TMVI, mitral valve replacement

CardiAQ Transcatheter Mitral Valve Implantation System image courtesy of CardiAQ Valve Technologies

Feature | Heart Valve Repair| July 13, 2015
Edwards Lifesciences Corp. announced that it has agreed to acquire CardiAQ Valve Technologies Inc., a privately held...
sentraheart lariet, LAA occlusion, FDA safety alert
Feature | Left Atrial Appendage (LAA) Occluders| July 13, 2015
The U.S. Food and Drug Administration (FDA) is alerting healthcare providers and patients of reports of patient deaths...
Feature | Business| July 08, 2015
Sorin S.p.A. and Cyberonics Inc. unveiled LivaNova as the name of their combined company, effective at the close of...
idarucizumab, dabigatran, anticoagulant, Boehringer Ingelheim, RE-VERSE AD
News | Antiplatelet and Anticoagulation Therapies| July 07, 2015
Results from an interim analysis of the Phase III RE-VERSE AD patient study demonstrate that 5 g of idarucizumab...
Overlay Init